The complaint filed by Glancy Prongay Wolke & Rotter LLP contends that Embecta executives provided unattainable revenue projections while failing to disclose critical weaknesses in the U.S. pen needle market. According to the court filings, these omissions rendered the company's public statements regarding its operational health materially misleading to shareholders.

Legal representatives for the potential class are currently soliciting inquiries from affected investors. Those interested in participating or seeking further information regarding their legal rights can reach Charles Linehan at the firm’s Los Angeles office via telephone at 310-201-9150 or through their official website. Participation in the class action does not require immediate legal action, as shareholders may choose to retain their own counsel or remain absent members of the class.